BRAINLIFE Brain Tumor Medical Database

Irinotecan

Home > Database > Treatment > Irinotecan (CPT-11)

Contents


Oligodendroglioma


Chamberlain MC, Glantz MJ
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma
J Neurooncol. 2008 Sep;89(2):231-8. Epub 2008 May 15
  Abstract

Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
Neurology. 2009 May 5;72(18):1601-6
  Abstract


Non-CNS Tumors


Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K
Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer
Cancer Chemother Pharmacol 2003 Apr 9; [epub ahead of print] 


Topoisomerase I inhibitors


Ewesuedo RB, Ratain MJ
Topoisomerase I Inhibitors
Oncologist 1997;2(6):359-364 (PDF Full Text)

 

This website is certified by Health On the Net Foundation. Click to verify. HOMEARCHIVES OF NEURO-ONCOLOGYCURRENT NEURO-ONCOLOGYGLIOBLASTOMA REPORTS
SERVICES: About BrainLife | Brain Tumor Medical Database | Children's Corner | Dedication | E-mail Alerts | Journals | Privacy Policy | Publications

This site complies with the HONcode standard for trustworthy health information: verify here bottom